News

Zacks Investment Research on MSN1d
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...
AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes
AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...
AbbVie says Phase 3 Verona trial of venetoclax/azacitidine did not meet endpoint
AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the ...
Morningstar3d
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
NORTH CHICAGO, Ill., June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly ...
AbbVie's Migraine Drug Achieves Superiority In Preventing Headaches Compared To Generic Treatment In Head To Head Trial
AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.
BioSpace2d
Roche, AbbVie’s Venclexta Stumbles Again, This Time in Myelodysplastic Syndromes
Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...
AbbVie fails in late-stage trial for Roche-partnered blood cancer therapy venetoclax
AbbVie (ABBV) stock in focus after a Phase 3 trial setback for leukemia therapy venetoclax marketed with Roche (RHHBY) in ...
Nasdaq3d
AbbVie's Phase 3 VERONA Study Of Venetoclax Plus Azacitidine In Myelodysplastic Syndrome Fails
(RTTNews) - AbbVie Inc. (ABBV) Monday said its Phase 3 VERONA study evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome ...
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) ...
Nasdaq1d
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study evaluated a combination therapy involving its blockbuster cancer drug ...